13th World ADC Europe 2023
With the recent approvals of ImmunoGen’s ELAHERE, Astrazeneca and Daiichi Sankyo’s DESTINY-Breast04, supporting Enhertu’s use in HER2-low breast cancer as a new therapeutically targetable category, the ADC space has continued to make major waves throughout 2022, a joy to see for oncology patients around the world. With more speakers, content, and networking opportunities than ever before, this is set to be the best version of the event yet and you cannot afford to miss it!
MabDesign members benefit from 10–15% discount on registration fees. Ask us for the code !
S'inscrire
Date
13-16 March 2023
Lieu
London
Organisateur
HansonWade
Prix
MabDesign members benefit from 10-15% discount on registration fees
Contact